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Extracapsular tumor spread and the risk of local, axillary and
supraclavicular recurrence in node-positive, premenopausal
patients with breast cancer
Abstract
BACKGROUND: Extracapsular tumor spread (ECS) has been identified as a possible risk factor for
breast cancer recurrence, but controversy exists regarding its role in decision making for regional
radiotherapy. This study evaluates ECS as a predictor of local, axillary, and supraclavicular recurrence.
PATIENTS AND METHODS: International Breast Cancer Study Group Trial VI accrued 1475 eligible
pre- and perimenopausal women with node-positive breast cancer who were randomly assigned to
receive three to nine courses of classical combination chemotherapy with cyclophosphamide,
methotrexate, and fluorouracil. ECS status was determined retrospectively in 933 patients based on
review of pathology reports. Cumulative incidence and hazard ratios (HRs) were estimated using
methods for competing risks analysis. Adjustment factors included treatment group and baseline patient
and tumor characteristics. The median follow-up was 14 years. RESULTS: In univariable analysis, ECS
was significantly associated with supraclavicular recurrence (HR = 1.96; 95% confidence interval
1.23-3.13; P = 0.005). HRs for local and axillary recurrence were 1.38 (P = 0.06) and 1.81 (P = 0.11),
respectively. Following adjustment for number of lymph node metastases and other baseline prognostic
factors, ECS was not significantly associated with any of the three recurrence types studied.
CONCLUSIONS: Our results indicate that the decision for additional regional radiotherapy should not
be based solely on the presence of ECS.
Annals of Oncology 19: 1393–1401, 2008
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Background: Extracapsular tumor spread (ECS) has been identified as a possible risk factor for breast cancer
recurrence, but controversy exists regarding its role in decision making for regional radiotherapy. This study evaluates
ECS as a predictor of local, axillary, and supraclavicular recurrence.
Patients and methods: International Breast Cancer Study Group Trial VI accrued 1475 eligible pre- and
perimenopausal women with node-positive breast cancer who were randomly assigned to receive three to nine
courses of classical combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil. ECS status
was determined retrospectively in 933 patients based on review of pathology reports. Cumulative incidence and
hazard ratios (HRs) were estimated using methods for competing risks analysis. Adjustment factors included treatment
group and baseline patient and tumor characteristics. The median follow-up was 14 years.
Results: In univariable analysis, ECS was significantly associated with supraclavicular recurrence (HR = 1.96; 95%
confidence interval 1.23–3.13; P = 0.005). HRs for local and axillary recurrence were 1.38 (P = 0.06) and 1.81 (P =
0.11), respectively. Following adjustment for number of lymph node metastases and other baseline prognostic factors,
ECS was not significantly associated with any of the three recurrence types studied.
Conclusions: Our results indicate that the decision for additional regional radiotherapy should not be based solely on
the presence of ECS.
Key words: axillary recurrence, breast cancer, extracapsular spread, extranodal invasion, loco-regional relapse
introduction
The results of trials from Denmark [1, 2] and British Columbia
[3] have revived not only the discussion about postmastectomy
radiotherapy but also about additional regional irradiation
as these trials used comprehensive treatment fields that
included the draining lymph nodes. A recent survey on the
current radiotherapeutic management of invasive breast cancer
in North America and Europe found marked differences in
physician opinions, e.g. internal mammary chain irradiation
was offered more often by European than North American
radiation oncologists, whereas those from North America were
more likely to irradiate the supraclavicular fossa and axilla [4].
Marked differences have also been reported by an informal
survey within participating centers of the International Breast
Cancer Study Group (IBCSG; formerly the Ludwig group);
this survey has shown that in several centers, postmastectomy
radiation therapy was given to patients with one to three
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positive lymph nodes only in the presence of additional risk
factors; furthermore, these risk factors, especially extracapsular
tumor spread (ECS) of axillary lymph nodes, also influenced
the decision about regional irradiation (Radiation Oncology
Task Force, IBCSG, unpublished data, April 2002).
ECS in axillary lymph node metastases is often associated
with locoregional failure (LRF) in breast cancer [5]. In
a previous report from our group, premenopausal patients with
ECS experienced a higher LRF rate as well as a worse disease-
free survival (DFS) and overall survival (OS) [6]. These worse
outcomes were statistically significant in univariable analyses,
but not after adjusting for the number of positive nodes. In
contrast, ECS with an extent of ‡2 mm was a significant
predictor of increased risk of LRF in uni- and multivariable
analyses, overall and in the subgroup of T1/T2 tumors with one
to three positive nodes in another report [5].
There is still controversy about the necessity of regional
irradiation in general, as well as in the presence of ECS, as only
a few publications have evaluated the prognostic role of ECS
and even fewer reports have dealt with the different sites of
relapse in these patients. The purpose of this retrospective
analysis is to evaluate the prognostic impact of ECS on the risk
of local, axillary, and supraclavicular recurrence in node-
positive premenopausal breast cancer patients treated within
one large randomized trial.
materials and methods
patients and treatments
From July 1986 to April 1993, 1475 eligible pre- and perimenopausal
women with node-positive breast cancer were randomly assigned to receive
three to nine courses of classical combination chemotherapy with
cyclophosphamide, methotrexate and fluorouracil (CMF) in a 2 · 2
factorial design: (i) CMF for six consecutive courses on months 1–6; (ii)
CMF for six consecutive courses on months 1–6 plus three single courses of
reintroduction CMF given on months 9, 12, and 15; (iii) CMF for
three consecutive courses on months 1–3; (iv) CMF for three consecutive
courses on months 1–3 plus three single courses of reintroduction CMF
given on months 6, 9, and 12 (IBCSG Trial VI) [7]. At 10 years’ median
follow-up, there were no significant differences in DFS or OS among or
between the four treatment groups in the eligible patient population. All
patients had a histologically proven node-positive unilateral breast cancer,
classified as T1a, T1b, T2a, T2b or T3a, pN1 M0 [International Union
Against Cancer (UICC) 1987], with either estrogen receptor (ER)-positive
or ER-negative status known. Surgery of the primary tumor was defined in
the protocol as either a total mastectomy with axillary clearance and no
radiotherapy or a breast-conserving procedure (quadrantectomy or
lumpectomy) with axillary lymph node dissection and subsequent local
radiotherapy. For women treated with breast-conserving surgery,
radiotherapy was postponed until the end of the initial phase of
chemotherapy (three or six courses). Details of eligibility, follow-up, patient
characteristics, and outcome for Trial VI have been previously reported [7].
ascertainment of ECS
Whether ECS was present or not was not asked on the trial case report
forms. This information was obtained retrospectively by reviewing the
protocol-required pathology reports for the 1475 eligible cases.
Determination of the presence or absence of ECS was on the basis of the
reported tumor–node–metastasis (TNM) category (UICC 1987) or, if the
TNM classification was not provided or not decisive (e.g. pN1biv), by
a clear statement in the pathology report about the presence or absence of
ECS. If the lymph node capsule was infiltrated but not penetrated, this was
considered ECS absent. Any penetration of the capsule was rated as ECS
present. It was not possible to determine the extent of ECS as this
information was seldom available. The ECS status could be determined for
933 patients (63%), and these patients form the basis for this report. The
role of ECS on LRF, DFS, and OS was recently published [6].
statistical analysis
This analysis considered the following three types of locoregional
recurrences: local, axillary, and supraclavicular. Local recurrence included
chest wall or mastectomy scar for patients whose definitive surgery was
mastectomy or ipsilateral breast recurrence for those who received a breast-
conserving procedure. Axillary recurrence included ipsilateral axillary nodes
and/or soft tissue of the axilla. Only the first documented recurrence was
considered, but the recurrence may have been in combination with other
sites. Internal mammary recurrence was also considered; however, only one
such event was recorded in the database, so this end point was not analyzed.
Time to recurrence was determined as the number of years from
randomization until the first proven recurrence. If no recurrence was
documented, then time to recurrence was censored at the last follow-up
time. Statistical methods for competing risks were used including
cumulative incidence and competing risks regression analysis [8–10].
Analysis for each type of recurrence was carried out separately. For each
type of recurrence, all other types (and death) were considered competing
risks. When evaluating a particular recurrence type, only those other
types of recurrence not in combination with the type of interest were
considered competing risks. Comparisons of cumulative incidence curves
were based on a K-sample test procedure [9]. All statistical tests based on
competing risks regression were Wald tests [10]. A two-sided P value <0.05
was considered statistically significant.
The analysis considered the following covariates: ECS, randomized
treatment group, type of surgery, age, ER status, number of involved lymph
nodes, number of lymph nodes examined, tumor size, and vessel invasion,
grouped as shown in Table 1. In descriptive analysis, number of positive
nodes was classified into five groups (1, 2–3, 4–6, 7–9, or 10+), while in
regression analysis, two groups were used (1–3 or 4+). In descriptive
analysis, number of nodes examined was classified into seven groups (1–4,
5–7, 8–10, 11–15, 16–20, 21–30, or 31+), while in regression analysis,
patients were divided into quartiles.
results
Table 1 describes the characteristics of the 933 patients with
ECS information. Results are shown for the overall patient
sample and for those with and without ECS. ECS is strongly
correlated with number of positive lymph nodes. Patients with
ECS tended to have higher numbers of positive nodes
(P < 0.0001). ECS was not significantly associated with any of
the other risk factors considered (Table 1).
The median follow-up is 14 years, with a maximum follow-
up of 20 years. A total of 139 local failures were observed.
The numbers of axillary and supraclavicular failures were 30
and 77, respectively. For patients with and without ECS, the
respective 10-year cumulative incidence rates were 14.6% and
11.6% for local failure, 4.1% and 2.1% for axillary failure,
and 9.8% and 5.8% for supraclavicular failure. Most relapses
were observed during the first 5 years of follow-up (72% of
local, 80% of axillary, and 77% of supraclavicular failures).
Figure 1 shows the cumulative incidence of each failure type
according to ECS status. For supraclavicular recurrences, the
presence of ECS was associated with a higher cumulative
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incidence (P = 0.004). For local recurrences, ECS tended to be
associated with higher cumulative incidence (P = 0.05). ECS
was also moderately associated with higher cumulative
incidence of axillary recurrence (P = 0.09).
Multivariable methods were used to evaluate the association
between ECS and failure type after adjustment for all the other
risk factors. Table 2 shows the hazard ratio (HR) for each
type of recurrence derived from competing risks regression
analysis without adjustment for any other risk factors. These
results are consistent with those shown in Figure 1; however,
the P values differ slightly because different test procedures
were used. In particular, ECS is strongly and significantly
associated with a higher risk for supraclavicular recurrences. It
is moderately, though not statistically significantly, associated
with the risk of local recurrence and the risk of axillary
recurrence. After adjustment for all covariates, ECS was no
longer a significant predictor (Table 2). Table 3 shows the HR
estimates from the multivariable competing risks regression
models for local, axillary, and supraclavicular recurrences,
respectively. It is noteworthy that the type of local treatment
(mastectomy versus BCS + RT) did not significantly influence
the pattern of locoregional recurrence. After removal of
nonsignificant predictors (except for ECS) using a backward
elimination approach, the estimated HRs for ECS were similar
to those shown in Table 3. Patients with ECS had a higher risk
of local failure [adjusted HR = 1.22; 95% confidence interval
(CI) 0.85–1.76]; however, it was not statistically significant
(P = 0.28). Significant predictors for supraclavicular recurrence
(Table 3) were adjuvant CMF treatment regimen and the
number of positive lymph nodes. For axillary recurrences, no
significant predictors were found.
Table 1. Patient characteristics
Total ECS No ECS P value
Number (%)
Total 933 (100) 462 (100) 471 (100)
Age, years
<40 181 (19) 81 (18) 100 (21) 0.15
‡40 752 (81) 381 (82) 371 (79)
Estrogen receptor status
Negative 269 (29) 132 (29) 137 (29) 0.86
Positive 664 (71) 330 (71) 334 (71)
No. of positive nodes
1 303 (32) 84 (18) 219 (46) <0.0001
2–3 301 (32) 135 (29) 166 (35)
4–6 159 (17) 102 (22) 57 (12)
7–9 84 (9) 67 (15) 17 (4)
‡10 86 (9) 74 (16) 12 (3)
No. of nodes examined
1–4 0 (0) 0 (0) 0 (0) 0.19
5–7 18 (2) 5 (1) 13 (3)
8–10 113 (12) 53 (11) 60 (13)
11–15 271 (29) 146 (32) 125 (27)
16–20 271 (29) 134 (29) 137 (29)
21–30 204 (22) 101 (22) 103 (22)
‡31 56 (6) 23 (5) 33 (7)
Tumor size
£2 cm 404 (43) 189 (41) 215 (46) 0.34
> 2 cm 515 (55) 266 (58) 249 (53)
Unknown 14 (2) 7 (2) 7 (1)
Vessel invasion
No 444 (48) 211 (46) 233 (49) 0.17
Yes 302 (32) 163 (35) 139 (30)
Unknown 187 (20) 88 (19) 99 (21)
Surgery
Mastectomy 643 (69) 329 (71) 314 (67) 0.13
Breast conserving 290 (31) 133 (29) 157 (33)
Chemotherapy
CMF · 6 239 (26) 125 (27) 114 (24) 0.71
CMF · 6 + 3 238 (26) 113 (24) 125 (27)
CMF · 3 225 (24) 113 (24) 112 (24)
CMF · 3 + 3 231 (25) 111 (24) 120 (25)
ECS, extracapsular tumor spread.
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Figure 1. Cumulative incidence functions for 933 premenopausal patients
with node-positive breast cancer randomized among four groups that differed
according to duration and timing of classical combination chemotherapy
with cyclophosphamide, methotrexate and fluorouracil according to presence
(solid line) or absence (dashed line) of extracapsular spread (ECS) for local
recurrence (A), axillary recurrence (B), and supraclavicular recurrence (C).
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Analyses were also carried out on the subgroups of one to
three and four or more positive lymph nodes (Table 4). Among
patients with one to three positive nodes, ECS was present in
219 of 604 patients (36%) and was significantly associated
with the number of positive lymph nodes. Eighty-four of 303
patients with one positive node (28%) were ECS positive versus
135 of 301 with two to three positive nodes (45%), P < 0.0001.
For patients with and without ECS, the respective 10-year
cumulative incidence rates were 11.1% and 10.5% for local
failure, 3.2% and 1.6% for axillary failure, and 6.9% and 5.0%
for supraclavicular failure. In this patient cohort, ECS was not
statistically significantly associated with risk of local
(unadjusted HR 1.13; 95% CI 0.71–1.80, P = 0.59), axillary
(unadjusted HR 1.88; 95% CI 0.67–5.28, P = 0.23), and
Table 2. Unadjusted and adjusted hazard ratiosa for ECS relative to no ECS based on competing risks regression analysis
Failure type Unadjusted hazard ratio 95% CI P value Adjusted hazard ratio 95% CI P value
Local 1.38 0.99–1.94 0.06 1.22 0.85–1.76 0.28
Axillary 1.81 0.87–3.78 0.11 1.48 0.65–3.37 0.35
Supraclavicular 1.96 1.23–3.13 0.005 1.54 0.92–2.56 0.10
aHazard ratios are for ECS relative to no ECS and are based on competing risks regression analysis with the following adjustment factors: treatment group,
age, estrogen-receptor status, number of positive nodes (1–3, ‡4), quartile of number of nodes examined, tumor size, vessel invasion and type of surgery.
ECS, extracapsular tumor spread.
Table 3. Multivariable competing risks regression models for local, axillary and supraclavicular recurrence
Predictor Local recurrence Axillary recurrence Supraclavicular recurrence
HR 95% CI P value HR 95% CI P value HR 95% CI P value
ECS
No 1.00 — 0.28 1.00 — 0.35 1.00 — 0.10
Yes 1.22 0.85–1.76 1.48 0.65–3.37 1.54 0.92–2.56
Treatment group
CMF · 6 1.00 — 0.35 1.00 — 0.35 1.00 — 0.05
CMF · 6 + 3 0.78 0.47–1.30 0.63 0.24–1.67 1.66 0.85–3.25
CMF · 3 1.24 0.79–1.92 0.36 0.12–1.12 2.07 1.09–3.91
CMF · 3 + 3 0.96 0.60–1.53 0.72 0.28–1.83 0.97 0.46–2.07
Age, years
<40 1.00 — <0.0001 1.00 — 0.99 1.00 — 0.13
40+ 0.46 0.32–0.67 0.99 0.39–2.54 0.66 0.38–1.13
Estrogen receptor status
Negative 1.00 — 0.05 1.00 — 0.53 1.00 — 0.27
Positive 1.52 0.99–2.31 1.32 0.56–3.11 0.75 0.45–1.25
Number of positive nodes
1–3 1.00 — 0.03 1.00 — 0.18 1.00 — 0.01
4+ 1.52 1.05–2.19 1.76 0.78–4.00 1.94 1.15–3.25
Number of nodes examined
1–11 1.00 — 0.009 1.00 — 0.68 1.00 — 0.41
12–15 0.50 0.30–0.82 1.07 0.36–3.18 1.09 0.58–2.05
16–20 0.74 0.47–1.16 1.10 0.40–3.03 0.67 0.33–1.36
21+ 0.49 0.30–0.79 0.61 0.19–1.96 0.78 0.40–1.51
Tumor sizea
£2 cm 1.00 — 0.39 1.00 — 0.52 1.00 — 0.17
>2 cm 1.24 0.85–1.82 1.35 0.55–3.29 1.68 0.97–2.91
Unknown 0.53 0.08–3.51 — — 1.10 0.13–9.01
Vessel invasion
No 1.00 — 0.03 1.00 — 0.16 1.00 — 0.60
Yes 1.64 1.12–2.40 1.30 0.53–3.19 1.31 0.77–2.25
Unknown 1.46 0.93–2.29 2.38 0.98–5.78 1.19 0.64–2.22
Surgery
Breast conserving 1.00 — 0.87 1.00 — 0.21 1.00 — 0.26
Mastectomy 0.97 0.65–1.43 1.89 0.69–5.19 0.74 0.43–1.26
aFor axillary recurrence, unknown tumor size was combined with £2 cm because of small numbers.
HR, hazard ratio; CI, confidence interval; ECS, extracapsular tumor spread.
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supraclavicular failure (unadjusted HR 1.52; 95% CI 0.78–2.96,
P = 0.22). Cumulative incidence in this group of patients is
shown in Figure 2.
Among patients with four or more positive nodes, ECS was
present in 243 of 329 patients (74%) and was significantly
associated with the number of positive lymph nodes (data not
shown). For patients with and without ECS, the respective
10-year cumulative incidence rates were 17.7% and 16.3% for
local failure, 4.9% and 4.7% for axillary failure, and 12.4% and
9.3% for supraclavicular failure. In this patient cohort, ECS
was not statistically significantly associated with risk of local
(unadjusted HR 1.27; 95% CI 0.69–2.30, P = 0.44), axillary
(unadjusted HR 1.07; 95% CI 0.35–3.29, P = 0.91) and
supraclavicular failure (unadjusted HR 1.56; 95% CI 0.73–3.36,
P = 0.25). Cumulative incidence in this group of patients is
shown in Figure 3.
discussion
In the literature, ECS is documented in the range of 24%–60%
of breast cancer cases [5, 6, 11–21]. Furthermore, in the era of
the sentinel node (SN) technique, several studies have shown
that the presence of ECS of the SN metastasis is a strong
predictor of non-SN tumor involvement in the axilla [22, 23].
The likelihood of ECS rises with the number of positive lymph
nodes [6], which makes determining an independent
prognostic role difficult. The first reports showing an
association of ECS with poorer outcome were published 30
years ago [24, 25] and were confirmed by almost every
subsequent study [12–14, 17, 26–28], but not in all [15, 18].
The interpretation of these studies is difficult as they all differ in
patient selection and the use of radiotherapy and systemic
treatments. Katz et al. [5] retrospectively analyzed the impact of
ECS in pre- and postmenopausal women with node-positive
breast cancer treated with mastectomy and anthracycline-
containing systemic therapies without radiotherapy in five
randomized trials at the MD Anderson Cancer Center between
1975 and 1994. ECS with an extent of ‡2 mm was a significant
predictor of increased risk of LRF in univariable and
multivariable analyses, overall and in the subgroup of T1/T2
tumors with one to three positive nodes. Interestingly, patients
with ‘ECS < 2 mm’ or ‘ECS not otherwise specified’ experienced
similar LRF rates compared with patients without ECS [5].
In a previous report of our group encompassing the patient
cohort of the current study, the impact of ECS was evaluated in
regard to LRF overall, DFS and OS [6]. At 10 years, 14%
[62% (standard error)] of patients without ECS experienced
LRF versus 18% (62%) of patients with ECS. The
corresponding rates for LRF with or without distant failure
were 19% (62%) versus 27% (62%). These differences
(DFS, OS, LRF, LRF with or without distant failure) were
statistically significant in univariable analyses. However, the
differences were no longer significant after adjusting for the
number of positive nodes [6].
Table 4. 10-Year cumulative incidence percent (standard error)
Recurrence type ECS No ECS
All patients
Local 14.6 (1.6) 11.6 (1.5)
Axillary 4.1 (0.9) 2.1 (0.7)
Supraclavicular 9.8 (1.4) 5.8 (1.1)
Patients with
one to three
positive nodes
Local 11.1 (2.1) 10.5 (1.6)
Axillary 3.2 (1.2) 1.6 (0.6)
Supraclavicular 6.9 (1.7) 5.0 (1.1)
Patients with
four or more
positive nodes
Local 17.7 (2.5) 16.3 (4.0)
Axillary 4.9 (1.4) 4.7 (2.3)
Supraclavicular 12.4 (2.1) 9.3 (3.2)
ECS, extracapsular tumor spread.
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Figure 2. Cumulative incidence functions for 604 premenopausal patients
with one to three positive lymph nodes according to presence (solid line)
or absence (dashed line) of extracapsular spread (ECS) for local recurrence
(A), axillary recurrence (B), and supraclavicular recurrence (C).
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Due to the lack of information in the literature, the aim of
the current analysis was to determine the relationship of ECS
status and different sites of locoregional relapses. There is
still controversy among radiation oncologists whether these
patients may benefit from regional irradiation.
In general, axillary failure rates are low [29], and in the
presence of ECS, 0%–5% of patients relapse in the axilla
without axillary irradiation: 1/122 (0.8%) [15], 1/43 (2.3%)
[26], 1/20 (5%) [13], 1/27 (3.7%) [17], and 0/6 (0%) [18]. As
the lower part of the axillary region is often encompassed by the
tangential chest/breast fields, series with no irradiation are
more appropriate for failure rate definition, but even then
axillary relapses were uncommon: 0/62 (0%) [27], 2/28 (7.1%)
[26], 6/82 (7%) [11], 0/43 (0%) [28], 1/85 (1.2%) [19], and
5/293 (1.7%) [30]. In our study, we observed axillary failures in
4% of patients with ECS compared with 2% in the absence of
ECS, which was of borderline statistical significance in
univariable analysis. However, no independent role could be
documented after adjustment for other risk factors. It is
interesting to note that for axillary failure, no significant
parameter could be found in multivariable analysis, which is
consistent with a recent analysis from the MD Anderson Cancer
Center [30]. After dissection of level I/II, axillary failure rates
were low and irradiation of the axilla was not indicated. The
presence of ECS did not modify the author’s recommendation.
There is even less data concerning the association of ECS with
supraclavicular failure. In the MD Anderson study, 20 of 142
patients with gross extranodal extension experienced
periclavicular failure. The 10-year actuarial failure rate was 19%,
whereas the corresponding numbers were 11% in the presence of
focal ECS and 6% in its absence [30]. In subgroup analyses
(one to three positive nodes, four or more positive nodes, T1/T2
and one to three positive nodes), the risk of periclavicular failure
was still higher for patients with gross ECS, but none of these
analyses was statistically significant. Nevertheless, the authors
recommend radiation to undissected regions (supraclavicular
fossa/axillary apex) in addition to the chest wall in patients with
gross extranodal extension regardless of the number of positive
lymph nodes [30]. Unfortunately, details about multivariable
analyses were not given and patients with ECS not otherwise
specified were pooled together with focal ECS [30].
We did not find a significant impact of ECS on
supraclavicular failure overall and in the subgroups of patients
with one to three or four or more positive nodes. We can,
therefore, not support irradiation of the periclavicular region/
axillary apex solely based on the finding of ECS. A limitation
of the current report is that the extent of ECS (focal versus
gross) was not reliably available in the pathology reports, and
one cannot exclude that significant differences could be
detected if analyses were restricted to gross ECS.
In conclusion, the current series reports by far the largest
evaluation of ECS in premenopausal patients prospectively
treated in one single randomized trial in which all patients
received the same chemotherapeutic agents. We are unable to
confirm an independent prognostic significance of ECS on
local, axillary, or supraclavicular failure. The decision for
additional regional radiotherapy should not be based solely on
the presence of ECS.
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